Modern Slavery Act Statement
June 2023

This statement is made on behalf of Dante Genome House Ltd and all the companies of the Dante Genomics Group Corp ("Dante Genomics Group") pursuant to the section 54(1) of the Modern Slavery Act 2015 and comprises our slavery and human trafficking statement.

This is Dante Genomics Group’s first statement issued under the Modern Slavery Act 2015. It outlines the steps we have taken as a business to identify and prevent slavery and human trafficking in our own operations and supply chains. We understand our responsibilities and are committed to improving our practices to combat slavery and human trafficking.

Dante Genomics Group is a specialist in whole genome sequencing, which has the potential to better our understanding of COVID-19 transmissibility and variants and could transform global healthcare systems and accelerate the implementation of precision medicine The Group has over 250 employees who operate in the UK.
Dante Genomics Group has direct relationships with a number of primarily UK based suppliers offering a wide range of services to the Group and also for the benefit of our customers (such as property management services). Our supply chains also include outplacement of IT services and certain other routine administrative tasks that are commoditised in nature. Outplacement is to a mix of onshore and offshore providers.
We are committed to ensuring that there is no modern slavery or human trafficking in our supply chains or in any part of our business. Our Anti-Slavery and Human Trafficking Policy reflects our commitment to acting ethically and with integrity in all our business relationships and to implementing and enforcing effective systems and controls to ensure slavery and human trafficking is not taking place anywhere in our business and in our supply chains. Accompanying this is our Whistleblowing Policy which provides a system for our employees to escalate slavery and human trafficking issues and breaches of our Group policies. Both policies are reviewed annually. There have been no breaches or suspected breaches of our Anti-Slavery and Human Trafficking Policy reported in 2022.

Supplier adherence to our Values and Ethics

We have zero tolerance to slavery and human trafficking. To ensure all those in our supply chain and contractors comply with our values we operate in line with principles of responsible sourcing, including paying employees at the prevailing minimum wage applicable within their relevant country of operations. We also have a Supplier Code of Conduct which outlines our expectations. The Supplier Code of Conduct lists the Dante Genomics Group Mandatory Policies and we expect Suppliers to adhere to these standards or higher. The relevant account managers will monitor and enforce compliance of the Supplier Code of Conduct.


To ensure a high level of understanding of the risks of modern slavery and human trafficking in our business, in our supply chains and in our business partners, we provide relevant in-house training to our colleagues. Under our Supplier Code of Conduct we also require our business partners to provide regular and relevant training to their staff and suppliers and providers.

Due diligence processes for Slavery and Human Trafficking

As part of our initiative to identify, monitor and mitigate against industry risk, business transaction risk and risk in the countries in which we operate, we nominate senior representatives of the business units and functions, who in turn report to the Group Risk and Compliance Committee chaired by the Enterprise Risk Director. We have in place policies and systems across our business; our trading partners; and our supply chains to:

Identify inappropriate employment practices
Identify, assess and monitor other potential risk areas
Mitigate the risk of slavery and human trafficking occurring
Protect Whistleblowers
Investigate reports of Modern Slavery

Next Steps

  • Raise awareness of the Anti-Slavery and Human Trafficking Policy and Supplier Code of Conduct with our employees and suppliers.
  • Additional training for employees as necessary.
  • Integrate any learnings from Covid-19 into our future strategy.


This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our Group’s slavery and human trafficking statement for the financial year ending 31st December 2022 and was approved by the Board of Directors of Dante Genomics Group in June 2023.

Tell us about your story, needs, or doubts.

Please complete the contact form to connect with the Dante Team. An expert will answer your request.

Dante Genomics is a leading global genomics and precision medicine company working to accelerate science to deliver better healthcare and ultimately save lives with a more human approach to health.

Let’s talk